Abstract Bayesian Optimal Interval (BOIN) designs are a class of model-assisted dose-
finding designs that can be used in oncology trials to determine the maximum tolerated dose …

In the era of precision oncology, improved understanding of tumor heterogeneity, particularly
at the molecular level, has caused a shift from traditionally histology based cancer drug …

In modern oncology drug development, adaptive designs have been proposed to identify the
recommended phase 2 dose. The conventional dose finding designs focus on the …

One of the primary objectives of an oncology dose‐finding trial for novel therapies, such as
molecular‐targeted agents and immune‐oncology therapies, is to identify an optimal dose …

One of the primary objectives of a dose-finding trial for novel anti-cancer agent combination
therapies, such as molecular targeted agents and immune-oncology therapies, is to identify …

Dose optimization is a critical stage of drug development in oncology and other disease
areas. Early phase clinical trials are inherently heterogeneous due to their exploratory …

Dose-finding studies are a critical part of the drug development cycle in oncology. Between
the severity of the disease and the typical toxicity of the treatments, oncology trials need to …

The primary purpose of an oncology dose‐finding trial for novel anticancer agents has been
shifting from determining the maximum tolerated dose to identifying an optimal dose (OD) …

For novel immuno‐oncology therapies, the primary purpose of a dose‐finding trial is to
identify an optimal dose (OD), defined as the tolerable dose having adequate efficacy and …

The primary objective of an oncology dose‐finding trial for novel therapies, such as
molecularly targeted agents and immune‐oncology therapies, is to identify the optimal dose …